HOME >> BIOLOGY >> NEWS
Novel therapeutic bortezomib moves to phase II trial in lung cancer patients

(NEW ORLEANS) -- A three-drug combination including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

The triple-therapy regimen will now be tested nationally in a phase II trial as first-line therapy for advanced non-small cell lung cancer. Angela Davies, assistant professor of hematology/oncology and principal investigator of the phase I trial, will lead the phase II trial as well.

The regimen consists of bortezomib, gemcitabine and carboplatin. Gemcitabine and carboplatin represent an accepted first-line treatment combination for advanced non-small cell lung cancer.

In the small phase I trial, the three drugs were administered on a similar schedule. Out of 12 patients, four had a partial response and seven had stable disease.

In the larger phase II trial, which will enroll 99 patients, the drugs will be given sequentially, with bortezomib following the chemotherapy drugs. Preclinical research at UC Davis Cancer Center suggests that giving bortezomib last may be more effective than giving it first or at the same time.

Bortezomib is a proteasome inhibitor that blocks the signals cancer cells rely on to degrade cellular proteins. The result is a buildup of proteins that hastens cell death.

Bortezomib has been approved by the Food and Drug Administration for the treatment of multiple myeloma, but had not been tested before in non-small cell lung cancer.

"Bortezomib is an exciting therapeutic, and we're encouraged that we've been able to take this promising three-drug combination immediately from phase I to phase II," Davies said.

Of the estimated 175,000 new cases of lung cancer diagnosed in the United States each year, nearly 80 percent are n
'"/>

Contact: Claudia Morain
530-219-5053
University of California, Davis - Health System
5-Jun-2004


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel approaches to current cellular therapies continue progress toward disease prevention
3. Novel therapies show promise against myeloid leukemia
4. Novel sensors help clear the air
5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2019)... ... August 28, 2019 , ... ... and Clinical Research Organization), have recently passed their five-year milestone of collaboration ... and psychoneuroendocrine stress expertise, with a primary focus towards performing feasibility studies, ...
(Date:8/27/2019)... , ... August 27, 2019 , ... ... service, is pleased to announce that it has partnered with Bertec, a leading ... designs and manufactures Balance Advantage systems, a full line of clinical systems for ...
(Date:8/27/2019)... ... 27, 2019 , ... Advancements with Ted Danson will focus ... to broadcast 4Q/2019. Check local listings for more information. , This segment ... The show will highlight how Debiopharm is working to champion the synergy between ...
Breaking Biology News(10 mins):
(Date:9/11/2019)... ... 2019 , ... Catalent, the leading global provider of advanced ... health products, today announced that Alex Haig, Senior Director, Engineering will present at ... Hall, Germany, on Sept. 18-19, 2019. , On Wednesday, Sept. 18 at 10:45 ...
(Date:9/8/2019)... (PRWEB) , ... September 05, 2019 , ... ... that Blaine Fitzgerald, former Vice President of Finance for Shopify, has been named ... Jones and healthcare venture capitalist Joel Finlayson as strategic advisors. Additionally, Spartan has ...
(Date:8/29/2019)... , ... August 29, 2019 , ... ... disease affecting grapevines, a feat they hope will ultimately help protect the multibillion-dollar ... including several Rochester Institute of Technology faculty and alumni sequenced the microbiome found ...
(Date:8/27/2019)... , ... August 27, 2019 , ... Dr. Kim Carlson ... recently opened North Peninsula Veterinary Surgical Group , a new surgical practice in ... are plans to expand and add more veterinary specialists as the practice grows. , ...
Breaking Biology Technology:
Cached News: